targeted therapies for dlbcl treatment
Published 4 years ago • 96 plays • Length 0:42Download video MP4
Download video MP3
Similar videos
-
1:28
how the standard of care for dlbcl is changing with the introduction of novel agents
-
1:09
the changing role of allosct in dlbcl in the era of novel agents
-
7:16
changes in the classification of dlbcl
-
3:04
applying molecular understanding of dlbcl to management strategies
-
1:53
the current immunotherapeutic landscape for treatment of dlbcl
-
3:58
phase ib/iia study of azd4573 acalabrutinib in r/r dlbcl
-
1:05
identifying high-risk dlbcl and optimizing treatment for these patients
-
1:33
zamtocabtagene autoleucel for the treatment of patients with r/r dlbcl
-
5:42
promising therapeutic efficacy of ebv-specific t-cell immunotherapy tabelecleucel in ptld
-
10:38
immunchemotherapie - behandlung der b-zell-lymphome
-
30:35
the genome of diffuse large b-cell lymphoma
-
1:12
exciting advances in dlbcl: molecular characterization of subtypes & novel immunotherapeutic agents
-
8:01
novel diagnostics & biomarkers for dlbcl and ctcl
-
0:57
the potential of the tsafinder tool in hematological oncology
-
1:53
preclinical research for the future of cellular therapies
-
1:50
the importance of identifying patients with limited-stage dlbcl
-
1:33
the difficulties of mrd detection in dlbcl
-
1:48
the potential of bispecific antibody-containing combinations in patients with b-cell lymphomas
-
6:28
outcomes following first-line therapy in routine clinical practice in alcl
-
1:02
the changing standard of care in dlbcl
-
1:15
personalized medicine for dlbcl
-
1:20
improving patient outcomes in ctcl: clinical collaboration and novel agents